Professional Documents
Culture Documents
Understand Pharmacovigilance
Define Postmarketing Surveillance
Describe the role of Center for Drug Evaluation and
Research (CDER) in FDAs Postmarketing Surveillance
programme.
Understand components of postmarketing drug
safety surveillance.
Understand the FDA Adverse Event Reporting
System (FAERS) and describe how adverse event
reports are collected and analyzed by
FDA/CDER/DPV
Understand regulatory requirements and the role of
MedWatch for reporting postmarketing safety
information.
by: Nashmia Zia
Reported information on a
possible causal relationship
between an adverse event and a
drug
The relationship being
previously unknown or
incompletely documented
Usually requires more than a
single case report to generate a
signal
Newly identified
atrisk population
Preclinical
Safety
&
Biological
Activity
Safety
&
Efficacy
Safety
&
Efficacy
A
P
P
R
O
V
A
L
PostMarketing
Safety
Surveillance
Safety Concerns
Center for
Food
Safety &
Applied
Nutrition
(CFSAN)
Center for
Veterinary
Medicine
(CVM)
Center for
Devices &
Radiological
Health (CDRH)
Center for
Biologics
Evaluation
& Research
(CBER)
Center for
Drug
Evaluation
& Research
(CDER)
Center for
Tobacco
Products (CTP)
Office of
Regulatory
Affairs (ORA)
Center for
Drug
Evaluation
& Research
(CDER)
Office of
Surveillance &
Epidemiology
CDER evaluates
the safety
profiles of drugs
available to
American
consumers
throughout the
life cycle of the
drugs
use this
information to
CDERs data of
premarket
safety
evaluation.
3. Active surveillance
Sentinel initiative
Voluntary
Adverse Effects
Any incident in which a medical product was suspected to
have resulted in an undesirable experience for the patient.
Product Use Error
Any medication or medical product error regardless of
patient involvement and outcome. Also report
circumstances that have the capacity to cause error, such
as similar label appearance.
Product Problem
Any concerns about the quality, authenticity, performance,
or safety of any medication or device
Problem with Different Manufacturer of Same Medicine
Any differences in therapeutic response after switching
from one manufacturer to another
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadF
orms/default.htm link for downloadable forms
Online
(www.fda.gov/medwatch)
Download the form
Mail
Fax 18003320178
Online Dietary Supplement & biologics Problem Reporting & Online Tobacco Product
Problem Reporting
https://www.safetyreporting.hhs.gov/fpsr/WorkflowLoginIO.aspx?metinstance=F3364E
33E164EBA7A4FE95252FEC184FCC304D42 link
Media attention
Litigation (class action lawsuits)
Nature of the adverse event
Type of drug product and indication
Length of time on market
Extent and quality of manufacturers surveillance
system
Rx or OTC product status
Reporting regulations
Voluntary
Manufacturer
FDA MedWatch
Regulatory
Requirements
FDA
FAERS
Database
5% of all reports
SAFETY SIGNAL
900,000
800,000
PERIODIC (Non-Expedited)
15-DAY (Expedited)
Number of Reports
700,000
DIRECT
600,000
500,000
400,000
300,000
200,000
100,000
2001
2002
2003
2004
2005
2006
2007
Calendar Ye ar
2008
2009
2010
2011
2012
elderly, children,
pregnant women,
comorbidities
Simple, relatively
inexpensive reporting
system
Did you
see it??
signal
Market withdrawal
CASE REPORTS
(MEDWATCH + SRP)
Voluntary & mandatory
FAERS
Identification of safety signal
Data mining
Different data bases + Sentinel database
Labeling changes
Enhanced Pharmacovigilance activities
Market withdrawal
by: Nashmia Zia